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Introduction
Breast cancer (BC) is the most common cancer in women. 
In Switzerland, 20% of the deaths caused by cancer are 
due to BC (1). In most epidemiological studies obesity is 
associated with an increased risk of postmenopausal BC, 
while an inverse relationship is observed in premenopausal 
women (2).
Overweight and obesity are considered at the present to 
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be the most important nutritional health risk in Western 
countries. Excessive body fatness is not only a risk factor for 
cardiovascular diseases and diabetes, but also for different 
types of cancers. In the last decades overweight and obesity 
have become a worldwide epidemic. The International 
Association for the Study of Obesity (IASO) estimates that 
300 million people around the world are obese and expects 
that obesity levels will continue to rise in the early 21st 
century and shortly become a global epidemic (3). The 
Food and Agricultural Organization of the United Nations 
points out that this problem does not only affect western 
countries as a considerable problem but, increasingly, 
developing countries as well (“the developing world’s new 
burden: obesity”) (4).
The impact of obesity on BC is complex and not 
yet completely understood (5) (for questions as to 
whether obesity itself is conductive to an environment 
of carcinogenesis, please see Box 1). There is not only 
an increase in postmenopausal BC in obese women, in 
addition, being obese has been shown to influence BC 
prognosis adversely (2,5-7,9-13) It has been suggested that 
a more advanced disease stage (12), more aggressive tumor 
characteristics at diagnosis (6) and suboptimal local and 
systemic treatment (14) of obese women in relation to and 
in comparison with patients of normal weight could explain 
the poorer prognosis.
In this review, we present the data and results from our 
project “The Impact of Overweight and Obesity on Breast 
Cancer: Data from Switzerland” which was initiated in 2009 
at the University Hospital Basel and the Institute of Social 
and Preventive Medicine (Division of Cancer Epidemiology 
and Prevention) of the University of Zürich.
The entire project comprised three major issues:
(I) The role of overweight and obesity in the etiology 
of BC (15);
(II) The relationship between overweight/obesity to 
diagnosis and the presenting characteristics of the 
tumor (16);
(III) The impact of BMI on patient compliance and 
persistence towards adjuvant BC therapy (17).
Our Swiss data is interesting because the general Swiss 
female population is distinctive in two areas compared to 
that of most other industrialized countries: (I) Switzerland 
has comparatively low rates of overweight (22-23%) and 
obesity (7-8%) in adult women and (II) has rather stable 
rates of overweight and obesity (18-20).
Data regarding the prevalence and development of 
overweight and obesity in Switzerland have been recorded 
since 1992 every 5 years by the Schweizerisches Bundesamt 
für Statistik (Swiss Federal Office of Statistics) within the 
Schweizerische Gesundheitsbefragungen (Swiss Health Surveys, 
SHS). In 2007, the fourth data collection was done. The 
existing four surveys, from 1992, 1997, 2002 and in 2007, 
were each carried out in representative, randomly selected 
samples comprising 20,000 to 30,000 private households with 
a telephone connection to represent the Swiss permanent 
population, i.e., male and female Swiss citizens and foreigners 
with a legal work permit aged 15 years and older (21).
In the survey from 2007, it was found that 21.7% of 
adult females were overweight [ow, body mass index (BMI) 
≥25-29.9] and an additional 8.1% were obese (ob, BMI 
≥30); in total, 29.8% of women in Switzerland showed a 
BMI ≥25 (20). Even if one considers that these Swiss results 
are self-reported data and that these, taken at face value, 
tend to underestimate obesity prevalence when compared 
to actual measured data (22), Switzerland is, in comparison 
Box 1 Tumor-promoting environment in obese patients (6-8).
Obesity influences the synthesis and bioavailability of the sexual hormones. Aromatase of the fat tissue converts androgenetic 
precursors produced by the adrenal and gonadal glands into estrogens. Furthermore, hyperinsulinemia leads to a decreased 
production of sexual binding hormone (SHBG) in the liver, thereby causing the level of bioavailable estrogen to rise. This 
stimulates the breast tissue and prohibits apoptosis. More central fat tissue is accompanied by an increased production of free 
fatty acids, adipokines, tumor-necrosis-factor-alpha (TNF-a) and resistin and a reduced release of adiponectin. Adiponectin raise 
the patient’s responsiveness to insulin while TNF-a and resistin do the opposite, resulting in a chronic resistance to insulin and 
hyperinsulinemia. Increased insulin concentrations lead to a decreased production of insulin-like-growth-factor-1 (IGF-1) binding 
protein in the liver. Therefore, the concentration of bioavailable IGF-1 increases. Insulin and IGF-1 encourage cell proliferation and 
inhibit apoptosis. Excessive central fat tissue is accompanied by subacute chronical inflammation. Adipocytes and lymphocytes, 
as well as macrophages produce adipokines and pro-inflammatory cytokines such as TNF-a, interleucin-6, interleucin-1 and 
plasminogen-activator-inhibitor-1, most of them creating an environment that encourages carcinogenesis (cell growth, survival 
and proliferation). In contrast, adiponectin stimulates the sensitivity of insulin and is anti-inflammatory.
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with international data, certainly in the lower range. The 
IASO has compiled the national data for the 27 countries of 
the European Union. On average, 47.5% of adult females 
showed a BMI ≥25 (ow: 29.5%; ob: 18.1%) (23). The USA 
clearly exceeds the European values with 61.8% of females 
with a BMI ≥25 (ow: 28.6%; ob: 33.2%) (24).
Notable in the Swiss results is not only the comparatively 
low prevalence of overweight and obesity, but also that 
the data have remained relatively stable over the last ten 
years (1997: ow: 21.8%; ob: 7.2%. 2002: ow: 22.7%; 7.8%. 
2007: see above) (18-20). Likewise, in a cross-sectional 
repeated survey of adults aged 35-74 years in Geneva, 
obesity prevalence did also not increase significantly in 
women between 1993 and 2004 (25). In contrast to this 
data, in nearly all other countries in the last 10-15 years, a 
considerable rise in obesity prevalence has been observed 
(“global epidemic”) (3,26,27).
The main BC data source of this project was the Basel 
Breast Cancer Database (BBCD). This web-based data 
documentation system records all newly diagnosed primary 
invasive BC cases treated at the University Women’s 
Hospital Basel, Switzerland since 1990. Data of in total 
1,459 patients up to 2009 were used for this project. 
The cases and their individual features and variables 
are summarized and recorded in 18 different forms. All 
together, a maximum of 349 variables can be coded per 
case. A standard case, i.e., a case without distant metastases 
in the further course of disease, includes approximately 150 
different variables: sociodemographic data, medical history, 
family history, clinical presentation at initial diagnosis, 
pathological characteristics, tumor staging, data on clinical 
management with reference to surgery, radiation and 
adjuvant and palliative treatment and follow-up status. The 
data are collected continuously. This database mirrors the 
development of BC diagnosis and treatment over a period 
of 20 years (e.g., increased diagnosis of non-palpable lesions 
by radiologic examinations, more breast-conserving surgery, 
trends in adjuvant systemic treatment, etc.). It is a particular 
strength of the BBCD project, that with a lost to follow-up 
rate of <3%, we have a complete documentation in nearly 
all cases.
From the 1,459 patients included in the BBCD, we had 
information on BMI in 97% of the cases (n=1,415). The 
clinicopathologic data of these 1,415 patients are listed 
in Table 1. The BMI was calculated using the following 
standard formula: body weight (kg)/height (m2). We used 
only directly measured BMI data taken at the time of initial 
BC diagnosis. Based on these data, BMI was calculated and 
categorized according to the WHO criteria as follows (31):
v BMI <18.5: underweight;
v BMI 18.5-24.9: normal (desirable) weight;
v BMI 25-29.9: overweight;
v BMI ≥30: obesity.
Data collection methods and the study design of this 
project were approved by the Ethical Review. The project 
was supported by the Krebsliga beider Basel; the sponsor had 
no influence whatsoever on the reported data.
Part I: the role of overweight and obesity in the 
etiology of postmenopausal breast cancer (15)
In 2007, the working group World Cancer Research Fund/
American Institute for Cancer Research reviewed the 
literature extensively, and after analyzing approximately 
200 studies, developed the following summary: while there 
is abundant and consistent epidemiological evidence and 
a clear dose response that greater body fatness is a risk 
factor for postmenopausal BC, it probably protects against 
premenopausal BC (2). For postmenopausal BC, a meta-
analysis was possible on 17 cohort studies, giving a summary 
effect estimate of 1.03 (95% CI: 1.01-1.04 per 2 kg/m2). 
The observed high heterogeneity of the 17 cohort studies 
may be explained in part by not adjusting for hormone 
replacement therapy (HRT). There is some evidence that 
body fatness increases the risk only in women not taking 
HRT. Because exogenous sources of estrogen, such as HRT, 
artificially elevate a woman’s circulating levels, they may 
mask any effect of increased endogenous estrogen from 
body fat (2).
Even though there is a substantial amount of consistent 
epidemiological evidence, the potential mechanisms 
through which body fatness might prevent premenopausal 
BC remain speculative. Furthermore, because BC diagnosed 
post menopause is much more common, a decreased risk of 
premenopausal BC would be outweighed by an increased 
risk of postmenopausal BC (2).
With regard to the question of whether body fatness poses 
a risk factor for the development of postmenopausal BC, 
there was no published data from Switzerland and in the first 
part of our project, we addressed this issue. Although we had 
nearly complete information regarding the menopausal status 
of the patients in the BBCD, we do not have this information 
in the data from the SHS. Since the mean age of menopause 
in the BBCD was 50.06 years, we used an age-dependent 
inclusion criterion and analyzed women from 51-80 years 
of age. We were aware of the fact that using this method 
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Table 1 Basel Breast Cancer Database 1990-2009: clinicopathologic characteristics of 1,415 patients with known BMI data (16)
Age at diagnosis: median [range] 61 [26-95]
Body mass index: median (range) 24.7 (14.3-53.3)
<18.5, n (%) 38 (2.7)
18.5-24.9, n (%) 712 (50.3)
25-29.9, n (%) 425 (30.0)
≥30, n (%) 240 (17.0)
Tumor size: median (mm) [range] 20 [0-220]
T1, n (%) 717 (50.7)
T2, n (%) 523 (37.0)
T3, n (%) 80 (5.7)
Non-inflammatory T4, n (%) 70 (5.0)
Inflammatory carcinoma (no tumor size recorded), n (%) 23 (1.6)
Missing (n) 2
TNM stage (28,29), n (%)
I 527 (37.2)
II 558 (39.5)
III 249 (17.6)
IV 81 (5.7)
Histological subtype, n (%)
Ductal invasive 1,097 (78.4)
Lobular invasive 197 (14.1)
Other types 106 (7.5)
Missing (n) 15
Grading, n (%)
G1/G2 786 (57.6)
G3 578 (42.4)
Missing (n) 51
Hormone receptor status, n (%)
ER positive/PR positive 867 (64.1)
ER negative/PR negative 239 (17.7)
Missing (n) 63 
HER2 receptor status [2002-2009]1, n (%) (known, n=660)
Positive 113 (17.1)
Triple negativity [2002-2009]1, n (%)
Positive 70 (10.6)
St. Gallen risk score (30) [2002-2009]1,2, n (%)
Low 82 (14.2)
Intermediate 400 (69.1)
High 97 (16.7)
ER, estrogen receptor; PR, progesterone receptor; 1, HER-2 has routinely been assessed for all patients since 2002 (n=665) and 
was available for 660 patients (46.6% of the entire study cohort); 2, only applicable for patients who had primary surgery (i.e., 
pTNM Classification) and known ER/PR/HER2 status, n=579.
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would lead to exclusion of certain groups (>51 years, 
premenopausal; <51 years, postmenopausal). However, 
with respect to the entire study group, the number of such 
patients is likely to be so small that it should not have a 
significant effect on the reported results.
Of all patients in the BBCD, 985 patients (65.7%) 
met our inclusion criteria; of these, information on BMI 
was available for 958 women; the mean age of this study 
subgroup was 65.0 years. From the 35,090 women who were 
interviewed in the SHS and provided information on BMI, 
14,476 women (37.2%) met our age-dependent inclusion 
criteria; the mean age of this subgroup was 63.7 years.
In this study, we compared objective BMI data (BBCD: 
measured) with subjective ones (SHS: self-reported). 
Since individuals included in population studies tend to 
underreport their weight and overestimate their height, 
obesity prevalence based on this data is often inaccurate 
(22,32). Since over- and under-reporting appears to be quite 
systematic, correction factors using separate adjustment 
factors resulted in an increase in the accuracy of self-
reported estimates (22,33,34). In this study, we used an 
equation developed by Hayes et al. (34). This calculation 
model was tested and approved for the Swiss population (35).
In the BBCD, data on body weight and height have 
been collected continuously since 1990. In the SHS, on 
the contrary, these data were only collected in the four 
years that the surveys were performed, namely 1992, 1997, 
2002 and 2007. In order to evaluate BMI distribution time 
trends over the last 20 years, we defined the four following 
subgroups:
v BBCD 1990-1994 vs. SHS 1992;
v BBCD 1995-1999 vs. SHS 1997;
v BBCD 2000-2004 vs. SHS 2002;
v BBCD 2005-2009 vs. SHS 2007.
The BMI distributions of the BBCD and the SHS study 
cohorts are shown in Table 2. Of the BBCD group, 309 
women (32.3%) were overweight and 188 women (19.6%) 
were obese at the time of the initial BC diagnosis. This data 
is comparable with a group of 337 BC patients >50 years 
who were registered in the Canton of Geneva between 2003 
to 2005 and of which 28% were overweight and 21% were 
obese (36).
In comparison, of women of the same age in the overall 
group of the SHS 1992 to 2007, 37.7% were overweight 
and 17.0% were obese. During the above mentioned four 
time periods considered in the BBCD, the prevalence 
of overweight were 35.5%, 36.3%, 31.3% and 27.8%, 
respectively; the prevalence of obesity were 15.0%, 23.8%, 
18.9%, and 21.2%, respectively (Table 3). For 51-80-year-old 
women of the four SHS of 1992, 1997, 2002 and 2007, 
the corresponding prevalence for overweight and obesity, 
corrected for self-report, were 38.6%, 37.8%, 38.5%, 
36.2% and 12.9%, 19.5%, 17.4% and 17.7%, respectively 
(Table 3).
Statistical tests for the overall course of time over the 
four periods revealed a comparable pattern in all tested 
categories of the SHS and the BBCD, respectively. For 
the category “overweight”, the tests for the overall course 
of time were not statistically significant. For the category 
“obesity”, there was a transient increase over time in the 
SHS (overweight and obesity increased between 1992 and 
1997. However, between 1997 and 2007, a statistically 
significant increase was no longer observed). The quadratic 
contrast was significant and negative, indicating a convex 
curvature, as can be seen in Figure 1. For the BBCD data, 
however, the test for the overall period of time was not 
statistically significant. Overall, there was no evidence of 
statistically significant differences between BBCD data and 
corrected and weighted SHS data in relation to overweight 
and obesity over the four time periods considered.
The existence of a consistent association between obesity 
and BC risk in countries with high obesity prevalence rates has 
been demonstrated time and again in the literature (2). This 
seems to indicate that there must be a higher prevalence of 
overweight and obesity in BC patients than in women of the 
same age in the general population. In the present analysis, 
Table 2 BMI distribution in 51-80 years old women of the BBCD between 1990 and 2009 in comparison to women of the same age in the 
SHS 1992 to 2007 (15)
Body mass index BBCD 1990-2009, n (%) SHS 1992-2007, n (%)
<18.5: underweight 22 (2.3) 203 (1.4)
18.5-24.9: normal weight 439 (45.8) 6,355 (43.9)
25-29.9: overweight 309 (32.3) 5,457 (37.7)
≥30: obesity 188 (19.6) 2,461 (17.0)
BBCD, Basel Breast Cancer Database; SHS, Swiss Health Survey; datasource, Swiss Federal Office (FSO).
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Table 3 Overweight and obesity in 51-80 years old women of the BBCD from 1990 to 2009 in comparison to women of the same age in 
the SHS 1992, 1997, 2002 and 2007 (15)
Time period Study group
Overweight (BMI 25-29.9) Obesity (BMI ≥30)
% 95% CI % 95% CI
1990-1994 BBCDa 35.5 29.4-42.0 15.0 10.6-20.2
1992 SHSb,c,d 38.6 37.3-39.8 12.9 12.4-13.5
1995-1999 BBCDa 36.3 29.5-43.5 23.8 18.0-30.5
1997 SHSb,c,d 37.8 36.5-39.1 19.5 18.8-20.3
2000-2004 BBCDa 31.3 25.5-37.5 18.9 14.2-24.4
2002 SHSb,c,d 38.5 37.4-39.6 17.4 16.8-18.0
2005-2009 BBCDa 27.8 22.7-33.3 21.2 16.6-26.4
2007 SHSb,c,d 36.2 35.2-37.3 17.7 17.1-18.3
a, BBCD, Basel Breast Cancer Database; b, SHS, Swiss Health Survey; data source, Swiss Federal Office (FSO); c, weighted to 
allow for non-responders and stratification in relation to age, gender, and nationality; d, data corrected for self report (35).
Figure 1 BMI distribution in 51-80 years old women of the Basel Breast Cancer Database (BBCD) between 1990 and 2009 in comparison 
to women of the same age in the Swiss Health Surveys [SHS, corrected for self report (35)]1 1992, 1997, 2002, and 2007 (15). 1, Datasource 
of the SHS: Swiss Federal Office (FSO); 1997, underweight n=28; 2, weighted, with 95% CI.
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however, no such difference was observed for our Swiss 
study group. This data does not correspond to that of most 
other industrialized countries, which have been affected by 
a considerable rise in obesity prevalence (37-42). A possible 
explanation for this observation may be a curvilinear dose-
response relationship between BMI and postmenopausal 
BC risk (2), so that an increased risk may only be observed 
in populations with a high prevalence of obese and very 
obese women.
Our data shows that findings from countries with high 
overweight/obesity prevalence may not unconditionally 
be applied to populations with comparably rather low 
overweight/obesity prevalence such as Switzerland. 
Compared to the USA, for example [approximately 50% 
of the cohort studies compiled in the WCRF/AICR review 
stem from the USA (2)], the obesity rates in Switzerland 
are actually half as high (43). It might be hypothesized 
that the association between obesity and BC risk cannot be 
explained by the factor BMI alone but also by a considerably 
different lifestyle (including numerous other insufficiently 
controllable other factors that might also facilitate 
carcinogenesis) that possibly also contribute to a condition 
where there are significantly more women with excessive 
body fatness.
A further explanation is that there might be a relationship 
between the increased risk of postmenopausal BC and 
central obesity. A Dutch study demonstrated that there was 
a correlation between central fat tissue and postmenopausal 
BC whereas there was no correlation between BC risk 
and BMI alone (44). This data is in line with study results 
from Italy which showed that there were more women 
with a metabolic syndrome in postmenopausal BC and 
that the level of central fat tissue increased the risk for BC 
significantly, again with no correlation for BMI alone (45).
Part II: the impact of BMI on prognostically 
relevant breast cancer tumor characteristics (16) 
For this second part of our project, we used the data of 
all patients of the BBCD with known BMI data (n=1,415 
patients). The predictor variable of this study was directly 
measured BMI data taken at the time of initial BC diagnosis. 
In a multivariate analysis, the patient’s age at the time of 
diagnosis was also considered. We evaluated the impact 
of BMI and age on the following prognostically relevant 
factors: tumor size (tumor detected by self-palpation or by 
radiological examination) and stage (28,29), histological 
subtype, grading, hormonal receptor status, HER2 status, 
“triple-negative” status (hormonal receptor and HER2 
status negative) and the risk score defined at the St. Gallen 
Expert Consensus Meeting in 2007 (30). Furthermore, 
we considered the tumor detection method and evaluated 
three different methods: self-detection, clinical breast 
examination and radiological breast examination including 
mammography and sonography.
As demonstrated in Table 4 and Figure 2, our data showed 
that BMI was significantly associated with tumor size (all 
patients: increase by 3 mm per 5 unit change in BMI: beta-
coefficient =0.03, P<0.001); this applied not only to the cases 
where the tumor was found by self-detection (P<0.001), but 
also to lesions detected by radiological breast examinations 
(P=0.044). In addition, a higher BMI was positively 
correlated with advanced TNM stage, unfavorable grading 
and a higher St. Gallen risk score. No associations were 
observed between BMI and histological subtype, estrogen 
receptor (ER) status, HER2 status and triple negative BC. 
Higher age, on the other hand, increased the probability 
of lobular instead of ductal BC, less triple negative BC, 
ER positivity and more favorable grading. In the subgroup 
of postmenopausal women, the above mentioned findings 
were attenuated but did not change the direction of the 
associations (Table 4).
Positive correlation with BMI in our cohort: tumor size, 
TNM stage, grading, St. Gallen risk score
There is increasing evidence that BMI is inversely associated 
with BC prognosis (2,5-7,9-13). It has been suggested 
that larger tumor size, more advanced stage and grade of 
the tumor at diagnosis (12) could explain in part this bad 
outcome. The findings of several studies are in accordance 
with this hypothesis (11,46); however, others are not (47). 
Accordingly, Wasserman et al. (48) observed no association 
between BMI and disease stage at diagnosis in 301 
postmenopausal women of the Women’s Healthy Eating and 
Living study. The same was true for women of any age in 
another study (49). Similarly, in the study by Chagpar et al., 
no association was observed between BMI and tumor size, 
lymph node status, or disease stage at diagnosis in mostly 
postmenopausal women with hormonally sensitive BC (47). 
In contrast, several other studies observed a positive 
association between BMI and disease stage, tumor size and 
lymph node status at diagnosis (10,46,50), as we did in our 
survey for tumor size and stage. In a study carried out in the 
Canton of Geneva, Switzerland (36), invasive carcinomas 
>1 cm were more frequently impalpable in obese women 
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Table 4 Association of BMI1 and age2 with prognostic relevant breast cancer characteristics (15)
95% CI (entire cohort) P value 95% CI (postmenopausal women) P value
Beta-coefficient
Tumor size (all patients)
BMI
Age
0.03 (0.01-0.05)
0.01 (0-0.02)
<0.001
0.082
0.03 (0.01-0.05)
0.01 (0.02-0.05)
0.002
<0.001
Tumor size (tumor detected by  
self-examination)
BMI
Age
0.05 (0.03-0.07)
0.001 (0-0.02)
<0.001
0.188
0.04 (0.02-0.06)
0.01 (–0.01-0.03)
<0.001
0.349
Tumor size (tumor detected by  
mammography or sonography)
BMI
Age
0.03 (0-0.07)
0 (–0.03-0.03)
0.044
0.840
0.03 (0.0-0.07)
0.02 (–0.03-0.06)
0.076
0.457
OR
TNM stage (III/IV vs. I/II)
BMI
Age
1.16 (1.02-1.31)
0.97 (0.89-1.06)
0.022
0.525
1.06 (0.92-1.23)
1.01 (0.88-1.17)
0.402
0.833
Histological type (lobular vs. ductal)
BMI
Age
1.04 (0.89-1.22)
1.18 (1.06-1.32)
0.602
0.003
1.05 (0.89-1.25)
1.09 (0.92-1.28)
0.573
0.324
Grading (3 vs. 1 and 2)
BMI
Age
1.11 (1.00-1.25)
0.91 (0.84-0.98)
0.057
0.019
1.10 (0.97-1.2)
0.91 (0.81-1.03)
0.135
0.151
ER status (positive vs. negative)
BMI
Age
0.95 (0.83-1.09)
1.23 (1.11-1.35)
0.459
<0.001
0.99 (0.84-1.16)
1.20 (1.02-1.40)
0.874
0.025
HER2 status (positive vs. negative)
BMI
Age
0.92 (0.74-1.15)
0.95 (0.82-1.10)
0.467
0.495
0.92 (0.72-1.18)
0.97 (0.77-1.22)
0.526
0.786
Triple negativity (yes vs. no)
BMI
Age
1.19 (0.93-1.52)
0.71 (0.59-0.86)
0.165
<0.001
0.87 (0.64-1.17)
1.35 (0.99-1.84)
0.350
0.052
St. Gallen risk score (high vs. low)
BMI
Age
1.24 (1.00-1.55)
0.88 (0.75-1.02)
0.049
0.091
1.20 (0.94-1.53)
0.89 (0.70-1.12)
0.154
0.308
BMI, body mass index; ER, estrogen receptor; CI, confidence interval; OR, odds ratio; 1, per 5 BMI unit; 2, per 10 years.
(22%) than in normal/underweight women (12%). It may 
be more difficult for clinicians and women to palpate a 
tumor in a large breast than in a small one. Thus, obese 
women with larger breasts may have larger tumors and 
more advanced tumor stages at diagnosis than lean 
women with small breasts. Accordingly, in a study of 2,863 
patients diagnosed with BC in Wisconsin, elevated BMI 
was associated with a greater probability of non-localized 
tumors in self-detected cancers, but in women, whose 
tumors were found by screening mammography or by 
clinical breast examination, BMI was not related to disease 
stage (51). In our Swiss cohort, however, BMI was found 
to be a significant factor for being diagnosed with larger 
tumors, both for lesions found by self-detection, as well as 
for those detected by radiological breast examinations. This 
could mean that either both methods for tumor detection 
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are impaired by large breasts, or larger tumors in larger 
breasts could be the consequence of obesity.
Non-adherence to BC screening is another possible 
explanation for our findings. The complex relationship 
between BMI and patient acceptance of the necessity 
of medical measures is well-examined with regard to 
mammography screening rates. Obese women are less 
likely to follow physician’s recommendations for breast and 
cervical cancer screening (52). On the basis of ten studies, 
Cohen et al. found among women in the U.S. that obesity is 
most likely a barrier to screening for BC (53). Some authors 
reported significantly less compliance to BC screening in 
obese women (52,54,55), whereas others did not confirm 
this finding in a large population-based analysis of more 
than 130,000 women (56). The reasons why a significant 
number of obese patients delay or refuse to participate in 
cancer screening programs are not yet fully understood. 
One of the most common reasons women give is the 
embarrassment of being weighed or having to undergo 
a physical examination with even more embarrassing 
aspects to endure (e.g., too small gowns, examination 
tables, instruments) (52,55,57). In our cohort, we could not 
comment on this explanation because up until now there 
exists only opportunistic screening in the Basel region.
No correlation between BMI and estrogen receptor status, 
HER2 status and triple-negative carcinoma in our cohort
Apart from the factors of presentation at a more advanced 
stage of disease at diagnosis and/or the difficulty in 
palpating the tumors, the observed worse outcome of obese 
BC patients may also be explained by the more unfavorable 
tumor characteristics in these patients. There are some data 
to support this hypothesis. Obesity is accompanied by the 
up-regulation of various cellular proliferation pathways (8). 
Adipokines and estrogens, produced in adipose tissue, may 
enhance tumor cell proliferation and metastasis (8,58,59), 
and may potentially result in more aggressive ER-positive 
cancers in post-menopausal women (60). 
The evidence of a positive association between body size 
and ER-positive BC is quite consistent (61-63). In a cohort 
study including 155,723 women of the Women’s Health 
Initiative, Phipps et al. found an increased risk of triple-
negative BC and ER-positive carcinomas for women in 
the highest versus lowest BMI quartile (64). Even though 
the ER-positive BC subtype has a rather good prognosis, 
obesity in postmenopausal women may result in more 
biologically aggressive ER positive tumors (60,65).
Obesity may affect BC risk by increasing circulating 
Figure 2 Scatter plot: tumor size in 1,415 breast cancer patients [1990-2009] dependent on BMI. Linear regression (BMI: increase on 
logarithmic scale per five BMI units, 0.03; 95% CI, 0.01-0.05; P<0.001; patient’s age: increase on logarithmic scale per 10 years, 0.01; 95% 
CI, 0.01-0.02; P=0.082. Broken line: regression line; continuous line: non-linear regression line. BMI, body mass index.
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endogenous estrogen levels (66). Thus, the association 
between body weight and BC risk may be modified by the 
tumor’s ER and PR status. Accordingly, the summarized 
findings of nine cohort and 22 case-control studies 
comparing the highest versus the reference categories of 
relative body weight observed that the risk for ER+PR+ 
tumors was 20% lower among premenopausal and 82% 
higher among postmenopausal women (63). No associations 
were observed for ER-PR- or ER+PR- tumors. More recent 
studies confirmed these findings (5,64,67,68). The association 
between BMI and BC risk is thus dependent on the tumor’s 
ER/PR status and the woman’s menopausal status, and in 
some studies the risk was modified by HRT (68-70).
The HER2 status may be inversely associated with 
BMI independent of ER status (71), as shown in a study of 
postmenopausal women. Phipps et al. on the other hand, 
found no difference in the association between BMI and 
HER2 status (64). Additional studies with sufficient numbers 
of HER2-positive and HER2-negative tumors are needed to 
clarify the association between HER2 status and BMI.
Data examining obesity as a risk factor for triple 
negative BC are limited and inconsistent (72,73). Case-
control studies that evaluated BMI in women irrespective 
of menopausal status and in postmenopausal women found 
no association with TNBC (73-76). The pooling of two 
case-control studies revealed a positive association between 
BMI and triple negative BC (OR, 2.7) in postmenopausal 
women not using hormone replacement therapy (75); no 
association was observed in HRT users. In a prospective 
study Phipps et al. observed for postmenopausal women in 
the highest versus the lowest BMI quartile a 1.35-fold non-
significantly increased risk of triple-negative carcinomas 
without association with HRT use (64).
Part III: the impact of BMI on patient compliance 
and persistence towards adjuvant breast cancer 
therapy (17)
“Overweight patients have less willpower and are less 
concerned about their health than non-obese patients”. 
There exists a great deal of negative stereotypical thinking 
regarding overweight and obese individuals and even 
physicians and care personnel are not immune to these 
commonly held stereotypical attitudes. Medical literature 
reports a considerable amount of evidence of these attitudes 
in doctors and nurses towards obese patients and this can 
be interpreted as an attitude of diminished respect for 
obese patients (52,77,78). This attitude is clearly felt by the 
patients, influencing them in their behavior and decisions 
(77-79). In order to test the above mentioned stereotype, 
we analyzed the impact of BMI on patient compliance and 
persistence towards adjuvant BC therapy. 
For this last part of our project, we used BBCD data 
concerning all patients with non-metastatic invasive BC, 
who received surgical therapy between 1997 and 2009. 
We restricted the analysis to women who were ≤75 years 
old at initial BC diagnosis. In total, 772 patients met these 
inclusion criteria. We had no BMI information for six of the 
772 patients; thus, 766 patients comprised our study cohort 
(Table 5). 
We deliberately analyzed the period since 1997. In 
doing that, we could make certain that our data reflects the 
current treatment situation as it covers a period in which 
most of the currently valid guidelines of treatment were 
already active (30):
v Surgery/radiation: from the beginning of our 
study period, the concept of breast conserving 
therapy (BCT) was implemented to the extent that 
approximately two thirds of the patients were treated 
by BCT. Postoperative radiation is an integral part of 
the BCT concept; thus, high BCT rates imply high 
rates of adjuvant radiation. 
v Chemotherapy: the introduction of new agents 
(above all the taxanes), as well as considerable 
advances  in  support ive  care  (above a l l  the 
introduction of anti-emetics such as the 5HT3 
antagonists) led to a situation where highly effective 
therapy concepts could be better implemented.
v Immunotherapy: trastuzumab was established as a 
standard treatment in patients with HER2-positive 
carcinomas.
v Endocrine therapy: in the late 1990s, endocrine 
therapy has become the gold standard not only for 
patients with advanced stage disease, but also for 
almost all patients with HR positive carcinomas. 
Furthermore, the introduction of the third-generation 
aromatase inhibitors in the adjuvant setting meant a 
crucial development in BC management.
v The treatment recommendations for all patients 
were based on the decision of the interdisciplinary 
tumor board of the University Hospital Basel. 
Bearing in mind the above mentioned negative 
stereotypes regarding overweight/obese patients, it is 
crucial for therapy recommendations to be made by 
an unprejudiced board, thereby averting a subjective 
decision by an individual physician. 
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Table 5 Compliance and persistence on adjuvant therapy. Data from the Basel Breast Cancer Database 1997-2009, included: patients ≤75 years 
old at initial BC diagnosis, n=766 (17)
n (%)
Surgery
Breast conserving therapy 499 (65.1)
Mastectomy 267 (34.9)
Surgical axillary staging (SLND/ALND) 752 (98.2)
Radiotherapy
Therapy not indicated/not recommended 155
Therapy recommended 611
Non-compliance 35 (5.7)
Therapy started 576
Therapy completed 574 (99.7)
Non-persistence 2 (0.3)
Chemotherapy
Therapy not indicated/not recommended 414
Therapy recommended 352
Non-compliance 42 (11.9)
Therapy started 310
Therapy completed 293 (94.5)
Non-persistence 17 (5.5)
Endocrine therapy
Therapy not indicated (HR-status negative) 143
Therapy indicated (HR-status positive) 623 
Therapy not recommended 8
Therapy recommended 615
Non-compliance 39 (6.3)
Lost to follow-up 6 (1.0)
Number of patients for persistence analysis1 473
Persistence 410 (86.7)
Therapy fully completed 341 (72.1)
Therapy discontinued due to death 10 (2.1)
Therapy discontinued due to BC recurrence 52 (11.0)
Therapy stopped due to medical reasons independent from BC and therapy-related adverse effects 7 (1.5)
Non-persistence 63 (13.3)
Abbreviations: SLND, sentinel lymph node dissection; ALND, axillary lymph node dissection HR, hormonal receptor; BC, breast 
cancer. 1In most cases, non-persistence to endocrine adjuvant therapy occurs within the first two years of therapy (80-82). Thus, 
we included patients with an ongoing therapy who took their medication for at least 36 months (n=89; 18.8%) and considered 
these patients as being persistent to therapy. Ninety-seven patients, who were diagnosed during 2008/2009, started oral endocrine 
therapy but had no follow-up time >36 months at the time of data analysis in April/May 2011, were not considered in the analysis of 
therapy persistence. Furthermore, six patients who started endocrine therapy but were lost to follow-up after a median observation 
time of 14 months (range, 1-25 months) were excluded from analysis.
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We had complete information regarding the type of surgery 
carried out and the receipt of adjuvant chemotherapy, and/
or radiation. As of 1997, adjuvant endocrine therapy has been 
the standard recommendation for all HR-positive patients, 
with few exceptions; the reasons not to recommend endocrine 
therapy included (I) a low-risk constellation (pT1a/b N0, 
favorable grading) and/or (II) advanced age of the patient 
with considerable co-morbidity.
We had complete information regarding the entire time 
period of adjuvant therapy for 758 patients of our study 
cohort (99.0%); eight patients (1.0%) were lost to follow-up.
A positive strength of our study was that we provided 
careful and detailed cl inical  follow-up with clear 
differentiation of the situations that led to denial or 
discontinuation of therapy; particular attention was given 
to a precise recording of the reasons for modifications and 
discontinuations.
In this study, we defined “compliance” as the readiness 
of the patient to accept a proposed adjuvant treatment or 
drug regimen. When the patients started the treatment, 
we used the term “persistence” (defined as the length 
of time from initiation to discontinuation of treatment) 
for the further application of therapy or intake of the 
drug regimen. According to previous studies on patient 
compliance and persistence towards endocrine adjuvant 
BC therapy in postmenopausal patients (80,83-86), we 
interpreted non-persistence mostly as an intentional action 
of the patients. According to this principle, patients who 
had to stop therapy due to local or systemic BC recurrence 
were not defined as non-persistent. The same holds true 
for cases where a physician decided to stop the therapy for 
medical reasons other than BC (e.g., in palliative situation 
of malignant diseases, dependence on nursing care, 
severe dementia). Furthermore, in accordance with other 
publications, patients who died from inter-current illness, 
having received therapy or medication shortly before death, 
were not considered non-persistent. We place a great deal 
of emphasis on the above mentioned criteria because non-
persistence as an intentional action may be preventable 
by more intensive care and improved counseling and we 
believe that a certain proportion of such patients may 
potentially be motivated to continue therapy. This option is 
clearly not available in a situation where the discontinuation 
of therapy was not a choice but was mandatory, e.g., due to 
the above mentioned situations.
There are few published studies that evaluated the 
impact of body weight on patient compliance and 
persistence towards BC therapy (5,87,88). Deglise et al. 
found no differences in the use of systemic adjuvant BC 
treatment between BMI categories of 460 patients (5). The 
authors defined “use of systemic treatment” if the respective 
treatment was prescribed as noted in the Geneva cancer 
registry; however, recommendation and prescription of 
a therapy does not necessarily mean an actual induction 
(compliance) and completion (persistence) of therapy. In a 
more recent study, Maskarinec et al. assessed the compliance 
with recommended treatment guidelines in 382 BC patients 
and found that the majority of obese patients did receive 
the recommended adjuvant treatment (88). The group of 
patients in which significantly less adjuvant treatment was 
given was the group of older patients. Buist and colleagues 
restricted their analysis as to whether the receipt of 
appropriate adjuvant therapy in BC patients differs by BMI 
to 897 patients ≥65 years and found that adequate adjuvant 
therapy was not associated with BMI (87).
Our data go even further. With respect to compliance, 
multivariate analyses calculated Odds ratios (ORs) >1 for 
increased BMI in all four therapy modalities, i.e., increased 
BMI had a positive influence on patient compliance (Table 6): 
the results were significant for radiotherapy (OR, 2.37; 
95% CI, 1.45-3.88; P<0.001) and endocrine therapy (OR, 
1.92; 95% CI, 1.21-3.04; P=0.002) and showed a trend in 
chemotherapy (OR, 1.42; 95% CI, 0.97-2.08; P=0.063). 
In the analysis of data relating to therapy persistence, 
increasing BMI had ORs <1 for chemotherapy, without 
reaching statistical significance. For endocrine therapy, 
increasing BMI was a significant predictor for persistence 
(OR, 1.35; 95% CI, 1.08-1.80; P=0.042) (Table 7). We did 
not analyze persistence rates of radiotherapy: once the 
radiation was started (n=576), only very few patients (n=2, 
0.3%) were non-persistent towards therapy (Table 5).
A possible reason for the high compliance (for 
radiotherapy, chemotherapy and endocrine therapy) 
and persistence (for endocrine therapy) in patients with 
increased BMI may be that this group’s somewhat strained 
relationship to screening and health education programs 
(6,52,54) as well as health care providers (77-79) does 
resolve itself once the hurdle of primary BC treatment is 
taken. Another factor could be that facing a new situation, 
which requires long-term medication such as adjuvant 
endocrine therapy, overweight/obese patients who often 
have to cope with other health issues due to co-morbidities 
requiring long-time medications (e.g., diabetes, hypertonia) 
are more reliable when it comes to taking an additional drug. 
Several studies reported a significant association between 
persistence with endocrine therapy and increasing numbers of 
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Table 6 Multivariate relationships between potential predictors 
and compliance to adjuvant BC therapy (17)
Odds ratio (95% CI) P value
Radiotherapy 
Increasing body mass indexa
Advanced ageb
2.37 (1.45-3.88)
0.68 (0.49-0.94) 
<0.001
0.016
Year of the initial diagnosis
1997-2000
2001-2004
2005-2009
St. Gallen risk score (30)
Low risk
Intermediate risk
High risk
Reference
0.50 (0.17-1.49)
0.65 (0.22-1.98)
Reference
0.80 (0.26-2.46)
0.48 (0.14-1.63)
0.215
0.451
0.699
0.023
Chemotherapy 
Increasing body mass indexa
Advanced ageb
1.42 (0.97-2.08)
0.53 (0.39-0.73) 
0.063
<0.001
Year of the initial diagnosis
1997-2000
2001-2004
2005-2009
St. Gallen risk score (30)
Low risk
Intermediate risk 
High risk
Reference
1.43 (0.55-3.75)
1.20 (0.50-2.86)
Reference
Not estimable
Not estimable
0.465
0.686
Endocrine therapy
Increasing body mass indexa
Advanced age b
1.92 (1.21-3.04)
1.56 (1.14-2.12) 
0.002
0.004
Year of the initial diagnosis
1997-2000
2001-2004
2005-2009
St. Gallen risk score (30)
Low risk
Intermediate risk
High risk
Reference
1.49 (0.60-3.69)
2.03 (0.81-5.09)
Reference
2.75 (1.25-6.02)
4.83 (1.57-14.81)
0.385
0.130
0.012
0.006
a, odds ratio is expressed as the ratio of an increase within 
five BMI values; b, odds ratio is expressed as the ratio of an 
increase within 10 years.
Table 7 Multivariate relationships between potential predictors 
and persistence to adjuvant BC therapy (17)
Odds ratio (95% CI) P value
Chemotherapy 
Increasing body mass indexa
Advanced ageb
0.71 (0.43-1.16)
0.41 (0.24-0.71) 
0.168
0.002
Year of the initial diagnosis
1997-2000
2001-2004
2005-2009
St. Gallen risk score (30)
Low risk
Intermediate risk
High risk
Reference
Not estimable
Not estimable
Reference
0.80 (0.26-2.46)
0.48 (0.14-1.63)
0.699
0.023
Endocrine therapy
Increasing body mass indexa
Advanced ageb
1.35 (1.08-1.80)
1.10 (0.86-1.41) 
0.042
0.464
Year of the initial diagnosis
1997-2000
2001-2004
2005-2009
St. Gallen risk score (30)
Low risk
Intermediate risk
High risk
Reference
1.54 (0.74-3.21)
0.77 (0.38-1.54)
Reference
0.86 (0.38-1.96)
1.05 (0.40-2.76)
0.245
0.451
0.728
0.927
a, odds ratio is expressed as the ratio of an increase within 
five BMI values; b, odds ratio is expressed as the ratio of an 
increase within 10 years.
other prescribed medications (89-91). It has been suggested 
that patients with a large medication burden develop routines 
to promote persistence and adherence (89,91).
As mentioned above, there is overwhelming evidence that 
overweight and obesity are associated with poor prognosis 
for both pre- and post-menopausal BC (2,5-7,9-13). 
The underlying mechanisms that can lead to decreased 
disease-specific and overall survival in these BC cancer 
patients are multiple and not yet entirely understood. In 
addition to the well-studied tumor-related characteristics 
of larger tumor size, more advanced stage of the disease 
and more aggressive tumor characteristics at diagnosis, 
there are host- and treatment-related factors contributing 
to the worse outcome in overweight/obese patients. 
Higher estrogen and testosterone hormone levels as 
well as concomitant hyperinsulinemia constitute a 
tumor-promoting environment and may therefore 
contribute to the patient’s poor survival (6,92). There are, 
however, contributing factors that are directly influenced 
either by the patient or the treating physician such as delayed 
or not-followed screening programs, reduced physical 
activity and weight gain (6,52,54) as well as the systematic 
under- t rea tment  by  empir i c  dose  reduct ions  o f 
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chemotherapy in overweight/obese BC patients (93,94).
The failure of the patient to comply and persist with 
adjuvant therapy, however, is not a contributing factor for 
the observed unfavorable prognosis in overweight/obese BC 
patients. In most therapy modes, patients with increasing 
BMI demonstrated a higher motivation and perseverance to 
the recommended treatment.
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